全文获取类型
收费全文 | 1358561篇 |
免费 | 98031篇 |
国内免费 | 2947篇 |
学科分类
医药卫生 | 1459539篇 |
出版年
2018年 | 12776篇 |
2016年 | 11455篇 |
2015年 | 12766篇 |
2014年 | 17865篇 |
2013年 | 26939篇 |
2012年 | 35467篇 |
2011年 | 37501篇 |
2010年 | 22144篇 |
2009年 | 21394篇 |
2008年 | 35709篇 |
2007年 | 38807篇 |
2006年 | 39210篇 |
2005年 | 37838篇 |
2004年 | 36711篇 |
2003年 | 35447篇 |
2002年 | 34996篇 |
2001年 | 63797篇 |
2000年 | 65478篇 |
1999年 | 55558篇 |
1998年 | 14930篇 |
1997年 | 13592篇 |
1996年 | 12216篇 |
1995年 | 12278篇 |
1994年 | 11497篇 |
1992年 | 42756篇 |
1991年 | 41303篇 |
1990年 | 40571篇 |
1989年 | 39553篇 |
1988年 | 36955篇 |
1987年 | 36415篇 |
1986年 | 34897篇 |
1985年 | 33106篇 |
1984年 | 24799篇 |
1983年 | 21006篇 |
1982年 | 12627篇 |
1981年 | 11518篇 |
1979年 | 23863篇 |
1978年 | 17020篇 |
1977年 | 14762篇 |
1976年 | 13334篇 |
1975年 | 15217篇 |
1974年 | 18041篇 |
1973年 | 17537篇 |
1972年 | 16791篇 |
1971年 | 15695篇 |
1970年 | 14876篇 |
1969年 | 14321篇 |
1968年 | 13439篇 |
1967年 | 11992篇 |
1966年 | 11242篇 |
排序方式: 共有10000条查询结果,搜索用时 296 毫秒
71.
Pancreatic ductal adenocarcinoma (PDAC) is predicted to become the second leading cause of cancer-related mortality within the next decade, with limited effective treatment options and a dismal long-term prognosis for patients. Genomic profiling has not yet manifested clinical benefits for diagnosis, treatment or prognosis in PDAC, due to the lack of available tissues for sequencing and the confounding effects of low tumour cellularity in many biopsy specimens. Increasing focus is now turning to the use of minimally invasive liquid biopsies to enhance the characterisation of actionable PDAC tumour genomes. Circulating tumour DNA (ctDNA) is the most comprehensively studied liquid biopsy analyte in blood and can provide insight into the molecular profile and biological characteristics of individual PDAC tumours, in real-time and in advance of traditional imaging modalities. This can pave the way for identification of new therapeutic targets, novel risk variants and markers of tumour response, to supplement diagnostic screening and provide enhanced scrutiny in treatment stratification. In the roadmap towards the application of precision medicine for clinical management in PDAC, ctDNA analyses may serve a leading role in streamlining candidate biomarkers for clinical integration. In this review, we highlight recent developments in the use of ctDNA-based liquid biopsies for PDAC and provide new insights into the technical, analytical and biological challenges that must be overcome for this potential to be realised. 相似文献
72.
73.
74.
75.
76.
77.
78.
Paul J. Devlin Brian W. McCrindle James K. Kirklin Eugene H. Blackstone William M. DeCampli Christopher A. Caldarone Ali Dodge-Khatami Pirooz Eghtesady James M. Meza Peter J. Gruber Kristine J. Guleserian Bahaaladin Alsoufi Linda M. Lambert James E. OBrien Erle H. Austin Jeffrey P. Jacobs Tara Karamlou 《The Journal of thoracic and cardiovascular surgery》2019,157(2):684-695.e8
Objective
Arch obstruction after the Norwood procedure is common and contributes to mortality. We determined the prevalence, associated factors, and practice variability of arch reintervention and assessed whether arch reintervention is associated with mortality.Methods
From 2005 to 2017, 593 neonates in the Congenital Heart Surgeons' Society Critical Left Heart Obstruction cohort underwent a Norwood procedure. Median follow-up was 3.7 years. Multivariable parametric models, including a modulated renewal analysis, were performed.Results
Of the 593 neonates, 146 (25%) underwent 218 reinterventions for arch obstruction after the Norwood procedure: catheter-based (n = 168) or surgical (n = 50) at a median age of 4.3 months (quartile 1-quartile 3, 2.6-5.7). Interdigitation of the distal aortic anastomosis was protective against arch reintervention. Development of ≥ moderate tricuspid valve regurgitation and right ventricular dysfunction at any point was associated with arch reintervention. Nonsignificant variables for arch reintervention included shunt type and preoperative aortic measurements. Surgical arch reintervention was protective against arch reintervention, but transcatheter reintervention was associated with increased reintervention. Arch reintervention was not associated with increased mortality. There was wide institutional variation in incidence of arch reintervention (range, 0-40 reinterventions per 100 years patient follow-up) and in preintervention gradient (range, 0-64 mm Hg).Conclusions
Interdigitation of the distal aortic anastomosis during the Norwood procedure decreased the risk of arch reintervention. Surgical arch reintervention is more definitive than transcatheter. Arch reintervention after the Norwood procedure is not associated with increased mortality. Serial surveillance for arch obstruction, integrated with changes in right ventricular function and tricuspid valve regurgitation, is recommended after the Norwood procedure to improve outcomes. 相似文献79.